Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | 0.650% | 0.654% | 4.054% | 10.791% | 10.791% | 1.316% | -48.790% |
| Beximco Pharmaceuticals Ltd. GDR | -1.780% | -1.778% | -1.778% | 6.250% | 6.250% | -25.714% | -58.692% |
| SELLAS Life Sciences Group Inc | -3.170% | 20.896% | 103.664% | 201.275% | 201.275% | 33.349% | -44.127% |
| Eledon Pharmaceuticals Inc. | 1.480% | 1.481% | 5.385% | -66.422% | -66.422% | -35.377% | -88.770% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat